Detalles de la búsqueda
1.
Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY.
Cancer Sci
; 111(12): 4510-4525, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-32954593
2.
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 20(12): 1655-1669, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31591063
3.
Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer: final results of a randomized, double-blind, placebo-controlled, phase 3 study.
Cancer
; 118(19): 4694-705, 2012 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22434360
4.
A phase II multicenter study of two different dosages of pemetrexed given in combination with cyclophosphamide as first-line treatment in patients with locally advanced or metastatic breast cancer.
Cancer Invest
; 30(4): 309-16, 2012 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-22468806
5.
RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability.
Drug Saf
; 45(1): 45-64, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34928484
6.
RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small Cell Lung Cancer.
Clin Cancer Res
; 27(19): 5258-5271, 2021 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34301751
7.
Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC.
J Thorac Oncol
; 16(2): 205-215, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33096270
8.
Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset.
JTO Clin Res Rep
; 2(6): 100171, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-34590023
9.
Patient-reported outcomes in RELAY, a phase 3 trial of ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small-cell lung cancer.
Curr Med Res Opin
; 36(10): 1667-1675, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32780643
10.
A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer.
Lung Cancer
; 137: 136-143, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31586771
11.
Phase II study of pemetrexed and cisplatin plus cetuximab followed by pemetrexed and cetuximab maintenance therapy in patients with advanced nonsquamous non-small cell lung cancer.
Lung Cancer
; 81(3): 428-434, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23790468
12.
PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
J Clin Oncol
; 31(34): 4349-57, 2013 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24145346
13.
Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer.
J Clin Oncol
; 27(11): 1753-60, 2009 Apr 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-19273714
Resultados
1 -
13
de 13
1
Próxima >
>>